drugset / Trial / NCT03585803
A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011
RandomizedParallel-groupSingle-blindTreatment
Summary
This trial is designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic of KMRC011 injection in healthy adult volunteers.
Timeline
- Start
- 2018-06-11
- Primary completion
- 2019-09-11
- Completion
- 2019-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XEMPRITOLIMOD | Protein / enzyme biologic | 5 ug | Intramuscular |
| Subject | XEMPRITOLIMOD | Protein / enzyme biologic | 10 ug | Intramuscular |
| Subject | XEMPRITOLIMOD | Protein / enzyme biologic | 15 ug | Intramuscular |
| Subject | XEMPRITOLIMOD | Protein / enzyme biologic | 30 ug | Intramuscular |
| Subject | XEMPRITOLIMOD | Protein / enzyme biologic | 45 ug | Intramuscular |